You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Dow
Mallinckrodt
Moodys
AstraZeneca

Last Updated: July 3, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021227


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

NDA 021227 describes CANCIDAS, which is a drug marketed by Merck and is included in one NDA. It is available from one supplier. Additional details are available on the CANCIDAS profile page.

The generic ingredient in CANCIDAS is caspofungin acetate. There are eight drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the caspofungin acetate profile page.
Summary for 021227
Tradename:CANCIDAS
Applicant:Merck
Ingredient:caspofungin acetate
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 021227
Suppliers and Packaging for NDA: 021227
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CANCIDAS caspofungin acetate POWDER;INTRAVENOUS 021227 NDA Merck Sharp & Dohme Corp. 0006-3822 0006-3822-10 1 VIAL, SINGLE-USE in 1 CARTON (0006-3822-10) > 10.8 mL in 1 VIAL, SINGLE-USE
CANCIDAS caspofungin acetate POWDER;INTRAVENOUS 021227 NDA Merck Sharp & Dohme Corp. 0006-3823 0006-3823-10 1 VIAL, SINGLE-USE in 1 CARTON (0006-3823-10) > 10.8 mL in 1 VIAL, SINGLE-USE
Paragraph IV (Patent) Challenges for 021227
Tradename Dosage Ingredient NDA Submissiondate
CANCIDAS POWDER;INTRAVENOUS caspofungin acetate 021227 2009-06-26

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;INTRAVENOUSStrength50MG/VIAL
Approval Date:Jan 26, 2001TE:APRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:POWDER;INTRAVENOUSStrength70MG/VIAL
Approval Date:Jan 26, 2001TE:APRLD:Yes

Expired US Patents for NDA 021227

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck CANCIDAS caspofungin acetate POWDER;INTRAVENOUS 021227-002 Jan 26, 2001   Start Trial   Start Trial
Merck CANCIDAS caspofungin acetate POWDER;INTRAVENOUS 021227-001 Jan 26, 2001   Start Trial   Start Trial
Merck CANCIDAS caspofungin acetate POWDER;INTRAVENOUS 021227-001 Jan 26, 2001   Start Trial   Start Trial
Merck CANCIDAS caspofungin acetate POWDER;INTRAVENOUS 021227-002 Jan 26, 2001   Start Trial   Start Trial
Merck CANCIDAS caspofungin acetate POWDER;INTRAVENOUS 021227-001 Jan 26, 2001   Start Trial   Start Trial
Merck CANCIDAS caspofungin acetate POWDER;INTRAVENOUS 021227-001 Jan 26, 2001   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Express Scripts
Merck
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.